Request Discount

Autoimmune Disease Drug Market (Indication - Diabetes Mellitus Type 1, Rheumatic Diseases, Multiple Sclerosis, Rare Diseases, and Other Indication; Drug Class - NSAIDs, Anti-inflammatory, Interferons, Antihyperglycemic, Immunosuppressants, and Other Drug Class; Distribution Channel - Hospital Pharmacies, Online Stores, and Retail Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : October, 2019

  • Rep Id : HC0750

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Autoimmune Disease Drug Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Autoimmune Disease Drug Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Autoimmune Disease Drug Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on autoimmune disease drug market provides an in-depth analysis of segments and sub-segments in the global as well as regional autoimmune disease drug market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional autoimmune disease drug market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global autoimmune disease drug market. According to the report, the global autoimmune disease drug market is projected to grow at a CAGR of 4.3% over the forecast period of 2019-2025.


Market Insight

Autoimmune diseases are diseases caused due to dysfunction of the immune system. The immune system is the body's defense against infections and diseases. However, sometimes the natural system of the body fails to recognize between own cells and foreign cells, leading to produce autoantibodies that kill normal cells and healthy tissues and can affect any body part. By far more than 80 autoimmune diseases are been identified which includes rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, etc. Out of these autoimmune diseases, some are life-threatening while some of them need treatment for a lifetime and some may also lead to disability. In female children and women, autoimmune disease is one of the leading causes of death.


An increasing population of autoimmune disease is one of the key factors driving the autoimmune disease drug market. As per the statistics of the National Institute of Health, approximately 23.5 million Americans have autoimmune diseases, among this 75 % are women. Moreover, initiatives taken by the government and private sector for spreading awareness regarding autoimmune disease is likely to boost the drug market. However, late or troublesome diagnosis owing to a lack of understanding of autoimmune diseases, their causes and their symptoms may hamper the growth of the market. Additionally, the long-term side effects of the drugs may also hold back the growth of the market. Furthermore, due to a substantial rise in biopharmaceutical research companies to generate innovative approaches and drugs for disease treatment as well as raising funds for the advancement of technologies will have greater opportunities for the autoimmune disease drug market during the forecast period.


Geographically, the market can be segmented into North America, Europe, Asia Pacific, and RoW. North America dominates the market due to its huge population affected by autoimmune disease and increasing research activities to speed up the development of new treatment options. Europe's market is expected to grow due to its escalation in awareness among people about autoimmune diseases and the involvement of government and private sectors to upgrade methods of diagnosis as well as prevention and management of the disease. On the other hand, the market in the Asia Pacific region is expected to grow during the forecast period owing to the considerable rise in healthcare expenditures.

Global Autoimmune Disease Drug Market


Segment Covered

The report on the global autoimmune disease drug market covers segments such as indication, drug class, and distribution channel. On the basis of indication, the sub-markets include diabetes mellitus type 1, rheumatic diseases, multiple sclerosis, rare diseases, and other indication. On the basis of drug class, the sub-markets include NSAIDs, anti-inflammatory, interferons, antihyperglycemic, immunosuppressants, and other drug class. On the basis of distribution channel, the sub-markets include hospital pharmacies, online stores, and retail pharmacies.


Companies Profiled:

The report provides profiles of the companies in the market such as F. Hoffmann-La Roche AG, Abbott Laboratories, Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson, AstraZeneca plc, Pfizer Inc., Novartis AG, and other companies.


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the autoimmune disease drug market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. 

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount